Compounds acting on appetite, blood sugar and energy expenditure — what the trials measured.
Not a peptide, never tested in a human, and sold at a fraction of the studied dose in a form that may not absorb. The mechanism is real; almost nothing else is settled.
A small molecule, not a peptide. It targets a drain on NAD+ that only exists in fat tissue — and only when that drain is already overexpressed.
Sixteen amino acids encoded outside the nucleus, acting through AMPK and travelling to the nucleus to change gene expression. Roughly 200 animal studies, and one human trial of an analogue.
GLP-1 and GIP together, an approved medicine, and the assumption the field got backwards. Plus the drug interaction most people miss.
One molecule acting on GLP-1, GIP and glucagon receptors at once. What each contributes, what the trials measured, and why it suppresses appetite less than semaglutide.
